

Lai Wei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/268728/publications.pdf>

Version: 2024-02-01

159
papers

6,209
citations

136940

32
h-index

85537

71
g-index

178
all docs

178
docs citations

178
times ranked

8909
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: A randomized clinical trial. <i>Hepatology</i> , 2022, 75, 182-195.	7.3	18
2	APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. <i>Hepatology International</i> , 2022, 16, 1-23.	4.2	45
3	Reply. <i>Hepatology</i> , 2022, 76, E30-E31.	7.3	1
4	Attitudes of Chinese Patients with Non-alcoholic Fatty Liver Disease Toward Participation in Clinical Trials from a National Multicenter Survey. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 464-473.	1.6	1
5	Impact of <scp>NAFLD</scp> on the outcome of patients with chronic hepatitis B in Asia. <i>Liver International</i> , 2022, 42, 1981-1990.	3.9	13
6	Midâ€upper arm circumference is associated with liver steatosis and fibrosis in patients with metabolicâ€associated fatty liver disease: A population based observational study. <i>Hepatology Communications</i> , 2022, 6, 2262-2272.	4.3	2
7	Metabolic abnormalities, liver and body fat in American <i>versus</i> Chinese patients with nonâ€alcoholic fatty liver disease. <i>JGH Open</i> , 2022, 6, 519-530.	1.6	2
8	Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning. <i>Clinical Infectious Diseases</i> , 2021, 72, 743-752.	5.8	25
9	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 46-60.e8.	4.4	27
10	AI-assisted CT imaging analysis for COVID-19 screening: Building and deploying a medical AI system. <i>Applied Soft Computing Journal</i> , 2021, 98, 106897.	7.2	271
11	Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy. <i>World Journal of Gastroenterology</i> , 2021, 27, 404-415.	3.3	7
12	TheÂAsian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. <i>Hepatology International</i> , 2021, 15, 223-257.	4.2	37
13	Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	1.4	2
14	Health-related quality of life in Chinese population with non-alcoholic fatty liver disease: a national multicenter survey. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 140.	2.4	15
15	The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 454-461.	3.7	70
16	Gd-EOB-DTPA-enhanced MRIâ€a noninvasive and short-term assessment method for liver necroinflammation after direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C. <i>Abdominal Radiology</i> , 2021, , 1.	2.1	0
17	Consensus on the secondary prevention of primary liver cancer. <i>Hepatology International</i> , 2021, 15, 1289-1300.	4.2	8
18	SGLT2 Inhibitors: A New Dawn for Recurrent/Refractory Cirrhotic Ascites. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	1.4	7

#	ARTICLE	IF	CITATIONS
19	Recent Advances in Adipose Tissue Dysfunction and Its Role in the Pathogenesis of Non-Alcoholic Fatty Liver Disease. <i>Cells</i> , 2021, 10, 3300.	4.1	25
20	Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus. <i>Journal of General Virology</i> , 2021, 102, .	2.9	1
21	China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis B. <i>Scandinavian Journal of Public Health</i> , 2020, 48, 233-239.	2.3	4
22	Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 457-467.e21.	4.4	56
23	Hepatitis B Virus Virions Produced Under Nucleos(t)ide Analogue Treatment Are Mainly Not Infectious Because of Irreversible DNA Chain Termination. <i>Hepatology</i> , 2020, 71, 463-476.	7.3	24
24	Correlation analysis of hepatitis C virus core antigen and low viral loads: Can core antigen replace nucleic acid test?. <i>Clinical and Experimental Medicine</i> , 2020, 20, 131-141.	3.6	6
25	Safety and efficacy of cobopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis. <i>Journal of Viral Hepatitis</i> , 2020, 27, 45-51.	2.0	4
26	Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1491-1500.	2.3	32
27	qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020, 71, 1953-1966.	7.3	66
28	STING expression in monocyte-derived macrophages is associated with the progression of liver inflammation and fibrosis in patients with nonalcoholic fatty liver disease. <i>Laboratory Investigation</i> , 2020, 100, 542-552.	3.7	64
29	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2020, 73, 1368-1378.	3.7	158
30	Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States. <i>Scientific Reports</i> , 2020, 10, 20922.	3.3	19
31	Glecaprevir and sofosbuvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 839-849.	8.1	32
32	Comparison of clinical outcomes and impact of SVR in American and Chinese patients with chronic hepatitis C. <i>JHEP Reports</i> , 2020, 2, 100136.	4.9	4
33	A Diagnostic Nomogram of Pathologic Grade for Preoperative Risk Stratification in Upper Tract Urothelial Carcinoma. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492092766.	1.3	4
34	An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials. <i>Diagnostics</i> , 2020, 10, 643.	2.6	12
35	RFX5 promotes the progression of hepatocellular carcinoma through transcriptional activation of KDM4A. <i>Scientific Reports</i> , 2020, 10, 14538.	3.3	15
36	Efficacy and safety of elbasvir/grazoprevir in treatment-naïve Chinese adults with hepatitis C virus infection: A randomized trial. <i>JGH Open</i> , 2020, 4, 1065-1073.	1.6	2

#	ARTICLE	IF	CITATIONS
37	A hook-effect-free homogeneous light-initiated chemiluminescence assay: is it reliable for screening and the quantification of the hepatitis B surface antigen?. <i>Annals of Translational Medicine</i> , 2020, 8, 606-606.	1.7	7
38	Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1092.	7.4	529
39	Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort. <i>Chinese Medical Journal</i> , 2020, 133, 253-261.	2.3	16
40	Reply. <i>Hepatology</i> , 2020, 72, 786-786.	7.3	0
41	Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-7.	1.4	2
42	Chinese guidelines on the management of liver cirrhosis (abbreviated version). <i>World Journal of Gastroenterology</i> , 2020, 26, 7088-7103.	3.3	49
43	FOXP3 expression in FOXP3+ tumor cells promotes hepatocellular cells metastasis. <i>Translational Cancer Research</i> , 2020, 9, 5868-5881.	1.0	4
44	Evaluation of an antigen assay for diagnosing acute and chronic hepatitis E genotype 4 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 458-465.	2.8	10
45	Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality. <i>EBioMedicine</i> , 2019, 46, 227-235.	6.1	26
46	Survey of Nonalcoholic Fatty Liver Disease Knowledge, Nutrition, and Physical Activity Patterns Among the General Public in Beijing, China. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3480-3488.	2.3	9
47	APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. <i>Hepatology International</i> , 2019, 13, 649-661.	4.2	72
48	How would China achieve WHO's target of eliminating HCV by 2030?. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 763-773.	4.4	30
49	Chinese guidelines on the management of ascites and its related complications in cirrhosis. <i>Hepatology International</i> , 2019, 13, 1-21.	4.2	45
50	Direct antiviral agents upregulate natural killer cell potential activity in chronic hepatitis C patients. <i>Clinical and Experimental Medicine</i> , 2019, 19, 299-308.	3.6	15
51	Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study. <i>Hepatology International</i> , 2019, 13, 573-586.	4.2	29
52	Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China. <i>BMC Gastroenterology</i> , 2019, 19, 65.	2.0	6
53	Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 311-325.	4.4	16
54	Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data. <i>Antiviral Therapy</i> , 2019, 24, 133-140.	1.0	9

#	ARTICLE	IF	CITATIONS
55	Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection. Journal of Medical Virology, 2019, 91, 1313-1318.	5.0	12
56	Utility of the EncephalApp Stroop Test for covert hepatic encephalopathy screening in Chinese cirrhotic patients. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1843-1850.	2.8	22
57	Genetic variation in <i>FCER1A</i> predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B. Journal of Viral Hepatitis, 2019, 26, 1040-1049.	2.0	3
58	Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1597-1603.	2.8	11
59	Regulatory factor X5 promotes hepatocellular carcinoma progression by transactivating tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta and suppressing apoptosis. Chinese Medical Journal, 2019, 132, 1572-1581.	2.3	16
60	Non-rigid Motion Correction for Ultrasound Localization Microscopy of the Liver in vivo. , 2019, , .		15
61	Fat Accumulation, Liver Fibrosis, and Metabolic Abnormalities in Chinese Patients With Moderate/Severe Versus Mild Hepatic Steatosis. Hepatology Communications, 2019, 3, 1585-1597.	4.3	8
62	Alcohol consumption analysis among patients with liver disease in China. Chinese Medical Journal, 2019, 132, 420-430.	2.3	10
63	Sofosbuvir+velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 127-134.	8.1	83
64	Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). Journal of Digestive Diseases, 2019, 20, 163-173.	1.5	111
65	Hepatitis E virus infection after haploidentical haematopoietic stem cell transplantation: incidence and clinical course. British Journal of Haematology, 2019, 184, 788-796.	2.5	8
66	PPPDE1 promotes hepatocellular carcinoma development by negatively regulate p53 and apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2019, 24, 135-144.	4.9	9
67	APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?. Hepatology International, 2019, 13, 103-109.	4.2	26
68	Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus. Clinical Gastroenterology and Hepatology, 2019, 17, 1929-1936.e1.	4.4	51
69	Awareness and Knowledge of Nonalcoholic Fatty Liver Disease Among Office Employees in Beijing, China. Digestive Diseases and Sciences, 2019, 64, 708-717.	2.3	17
70	Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China. Journal of Clinical and Translational Hepatology, 2019, 7, 1-8.	1.4	12
71	Chinese guidelines on management of hepatic encephalopathy in cirrhosis. World Journal of Gastroenterology, 2019, 25, 5403-5422.	3.3	28
72	Real-World Clinical Outcomes among Individuals with Chronic HCV Infection in China: CCgenos Study. Antiviral Therapy, 2019, 24, 473-483.	1.0	4

#	ARTICLE	IF	CITATIONS
73	Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B. <i>Journal of Clinical and Translational Hepatology</i> , 2019, X, 1-7.	1.4	8
74	Application of plasma circulating cell-free DNA detection to the molecular diagnosis of hepatocellular carcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 1428-1445.	0.0	8
75	HBsAg stimulates NKG2D receptor expression on natural killer cells and inhibits hepatitis C virus replication. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 233-240.	1.3	3
76	Ledipasvir/sofosbuvir for treatment-naïve and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study. <i>Hepatology International</i> , 2018, 12, 126-132.	4.2	19
77	Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1168-1176.	2.8	17
78	An Assessment of Upper Limits of Normal for ALT and the Impact on Evaluating Natural Course of Chronic Hepatitis B Virus Infection in Chinese Children. <i>American Journal of Gastroenterology</i> , 2018, 113, 1660-1668.	0.4	7
79	Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized CORAL study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 34, 12-21.	2.8	20
80	Profile of the VERSANT HCV genotype 2.0 assay. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 995-1004.	3.1	6
81	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. <i>PLoS ONE</i> , 2018, 13, e0199198.	2.5	6
82	Hepatitis E virus infection in acute non-traumatic neuropathy: A large prospective case-control study in China. <i>EBioMedicine</i> , 2018, 36, 122-130.	6.1	30
83	Risk factors for familial clustering of hepatitis C virus infection in a Chinese Han population: a cross-sectional study. <i>BMC Public Health</i> , 2018, 18, 708.	2.9	7
84	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1429-1437.	2.0	16
85	A cross-sectional assessment of health-related quality of life in Chinese patients with chronic hepatitis c virus infection with EQ-5D. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 124.	2.4	28
86	MYL6B, a myosin light chain, promotes MDM2-mediated p53 degradation and drives HCC development. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 28.	8.6	24
87	The experience of discrimination of individuals living with chronic hepatitis B in four provinces of China. <i>PLoS ONE</i> , 2018, 13, e0195455.	2.5	23
88	HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. <i>Antiviral Research</i> , 2018, 158, 178-184.	4.1	17
89	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. <i>Journal of Hepatology</i> , 2018, 69, 896-904.	3.7	1,157
90	Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir. <i>World Journal of Gastroenterology</i> , 2018, 24, 4554-4564.	3.3	9

#	ARTICLE	IF	CITATIONS
91	Effect of Upregulated DNA Replication and Sister Chromatid Cohesion 1 Expression on Proliferation and Prognosis in Hepatocellular Carcinoma. Chinese Medical Journal, 2018, 131, 2827-2835.	2.3	26
92	Hepatitis E Virus Infection after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence and Clinical Course. Blood, 2018, 132, 5734-5734.	1.4	0
93	Hepatitis C Virus Genotype Analyses in Chronic Hepatitis C Patients and Individuals With Spontaneous Virus Clearance Using a Newly Developed Serotyping Assay. Journal of Clinical Laboratory Analysis, 2017, 31, .	2.1	3
94	The transcription factor RFX5 is a transcriptional activator of the TPP1 gene in hepatocellular carcinoma. Oncology Reports, 2017, 37, 289-296.	2.6	25
95	Influences on viral replication and sensitivity to GLS4, a HAP compound, of naturally occurring T109/V124 mutations in hepatitis B virus core protein. Journal of Medical Virology, 2017, 89, 1804-1810.	5.0	8
96	CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatology International, 2017, 11, 221-241.	4.2	206
97	PPPDE1 is a novel deubiquitinase belonging to a cysteine isopeptidase family. Biochemical and Biophysical Research Communications, 2017, 488, 291-296.	2.1	18
98	Automated evaluation of liver fibrosis in thioacetamide, carbon tetrachloride, and bile duct ligation rodent models using second-harmonic generation/two-photon excited fluorescence microscopy. Laboratory Investigation, 2017, 97, 84-92.	3.7	28
99	Temporal Changes in the Modes of Hepatitis C Virus Transmission in the USA and Northern China. Digestive Diseases and Sciences, 2017, 62, 2141-2149.	2.3	4
100	Risk Assessment of Hepatocellular Carcinoma in Patients with Hepatitis C in China and the USA. Digestive Diseases and Sciences, 2017, 62, 3243-3253.	2.3	12
101	Abnormal phenotypic features of IgM+B cell subsets in patients with chronic hepatitis C virus infection. Experimental and Therapeutic Medicine, 2017, 14, 1846-1852.	1.8	2
102	Serum HBV core-related antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients. Journal of Medical Virology, 2017, 89, 463-468.	5.0	31
103	Real-world treatment patterns and clinical outcomes of HCV treatment-naïve patients in China: an interim analysis from the CCgenos study. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 244-252.	2.8	27
104	Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B. Current Medical Research and Opinion, 2017, 33, 495-504.	1.9	20
105	Second Harmonic Generation Reveals Subtle Fibrosis Differences in Adult and Pediatric Nonalcoholic Fatty Liver Disease. American Journal of Clinical Pathology, 2017, 148, 502-512.	0.7	18
106	Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). Journal of Clinical and Translational Hepatology, 2017, 5, 297-318.	1.4	181
107	Efficacy of Real-world Entecavir Therapy in Treatment-naïve Chronic Hepatitis B Patients. Chinese Medical Journal, 2017, 130, 2190-2197.	2.3	9
108	Patient Education Improves Patient Knowledge and Acceptance on Antiviral Therapy of Hepatitis C in Rural China. Chinese Medical Journal, 2017, 130, 2750-2751.	2.3	5

#	ARTICLE	IF	CITATIONS
109	HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways. <i>PLoS Pathogens</i> , 2017, 13, e1006658.	4.7	105
110	Obeticholic acid improves hepatic steatosis and inflammation by inhibiting NLRP3 inflammasome activation. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 8119-8129.	0.5	1
111	HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b. <i>Chinese Medical Journal</i> , 2016, 129, 2212-2219.	2.3	17
112	Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. <i>PLoS ONE</i> , 2016, 11, e0155934.	2.5	34
113	Survey of hepatitis B knowledge and stigma among chronically infected patients and uninfected persons in Beijing, China. <i>Liver International</i> , 2016, 36, 1595-1603.	3.9	59
114	GII.4 Sydney_2012 norovirus infection in immunocompromised patients in Beijing and its rapid evolution in vivo. <i>Journal of Medical Virology</i> , 2016, 88, 224-233.	5.0	11
115	Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B. <i>Scientific Reports</i> , 2016, 6, 37498.	3.3	13
116	APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. <i>Hepatology International</i> , 2016, 10, 681-701.	4.2	75
117	Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study. <i>Journal of Hepatology</i> , 2016, 65, 674-682.	3.7	36
118	APASL consensus statements and recommendation on treatment of hepatitis C. <i>Hepatology International</i> , 2016, 10, 702-726.	4.2	189
119	Nationwide survey of specialist knowledge on current standard of care (PegIFN/RBV) and barriers of care in chronic hepatitis C patients in China. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1995-2003.	2.8	9
120	A Comparative Study of Liver Disease Care in the USA and Urban and Rural China. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2847-2856.	2.3	2
121	Hepatitis B virus infection in Chinese patients with hepatitis C virus infection: prevalence, clinical characteristics, viral interactions and host genotypes: a nationwide cross-sectional study. <i>BMJ Open</i> , 2016, 6, e012016.	1.9	12
122	HBsAg and HBeAg in the prediction of a clinical response to peginterferon α -2b therapy in Chinese HBeAg-positive patients. <i>Virology Journal</i> , 2016, 13, 180.	3.4	6
123	Simeprevir plus peginterferon/ribavirin for HCV genotype 1a infected treatment-naïve patients in China and South Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 912-920.	2.8	8
124	Serum viral duplex-linear DNA proportion increases with the progression of liver disease in patients infected with HBV. <i>Gut</i> , 2016, 65, 502-511.	12.1	28
125	The Lumipulse G HBsAg-Quant assay for screening and quantification of the hepatitis B surface antigen. <i>Journal of Virological Methods</i> , 2016, 228, 39-47.	2.1	30
126	Treating chronic hepatitis B virus: Chinese physicians' awareness of the 2010 guidelines. <i>World Journal of Hepatology</i> , 2016, 8, 762.	2.0	2

#	ARTICLE	IF	CITATIONS
127	Delivery of cell-penetrating peptide-peptide nucleic acid conjugates by assembly on an oligonucleotide scaffold. <i>Scientific Reports</i> , 2015, 5, 17640.	3.3	28
128	Deep sequencing of hepatitis B virus basal core promoter and precore mutants in HBeAg-positive chronic hepatitis B patients. <i>Scientific Reports</i> , 2015, 5, 17950.	3.3	21
129	Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. <i>Advances in Therapy</i> , 2015, 32, 727-741.	2.9	19
130	Abnormal CD4 ⁺ T helper (Th) 1 cells and activated memory B cells are associated with type III asymptomatic mixed cryoglobulinemia in HCV infection. <i>Virology Journal</i> , 2015, 12, 100.	3.4	10
131	Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection. <i>PLoS ONE</i> , 2015, 10, e0138756.	2.5	8
132	Prevalence and characterization of hepatitis B and C virus infections in a needle-sharing population in Northern China. <i>BMC Public Health</i> , 2015, 15, 460.	2.9	10
133	Evaluation of the Elecsys [®] Anti-HCV II assay for routine hepatitis C virus screening of different Asian Pacific populations and detection of early infection. <i>Journal of Clinical Virology</i> , 2015, 64, 20-27.	3.1	20
134	Absolute quantification of serum microRNA-122 and its correlation with liver inflammation grade and serum alanine aminotransferase in chronic hepatitis C patients. <i>International Journal of Infectious Diseases</i> , 2015, 30, 52-56.	3.3	32
135	Up-regulation of interleukin-22 mediates liver fibrosis via activating hepatic stellate cells in patients with hepatitis C. <i>Clinical Immunology</i> , 2015, 158, 77-87.	3.2	49
136	Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. <i>Hepatology International</i> , 2015, 9, 486-507.	4.2	18
137	Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 141.	8.6	186
138	Early predictive efficacy of core antigen on antiviral outcomes in genotype 1 hepatitis C virus infected patients. <i>Brazilian Journal of Infectious Diseases</i> , 2015, 19, 390-398.	0.6	3
139	STING Agonists Induce an Innate Antiviral Immune Response against Hepatitis B Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1273-1281.	3.2	93
140	Pretreatment serum macrophage inflammatory protein (MIP)-1 levels predict sustained virological responses to re-treatment in patients with chronic hepatitis C virus infection. <i>International Journal of Infectious Diseases</i> , 2015, 33, 15-21.	3.3	4
141	Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus. <i>Chinese Medical Journal</i> , 2015, 128, 2625-2631.	2.3	14
142	Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology</i> (Australia), 2014, 29, 545-553.	2.8	113
143	Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection. <i>BMC Gastroenterology</i> , 2014, 14, 47.	2.0	10
144	Performance Comparison of the Versant HCV Genotype 2.0 Assay (LiPA) and the Abbott RealTime HCV Genotype II Assay for Detecting Hepatitis C Virus Genotype 6. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3685-3692.	3.9	38

#	ARTICLE	IF	CITATIONS
145	Impact of New Hepatitis C Treatments in Different Regions of the World. <i>Gastroenterology</i> , 2014, 146, 1145-1150.e4.	1.3	48
146	Effect of abstinence from alcohol on survival of patients with alcoholic cirrhosis: A systematic review and meta-analysis. <i>Hepatology Research</i> , 2014, 44, 436-449.	3.4	47
147	Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients. <i>Hepatology International</i> , 2014, 8, 72-82.	4.2	11
148	Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: A randomized trial. <i>Journal of Clinical Virology</i> , 2014, 61, 509-516.	3.1	14
149	An interferon-beta promoter reporter assay for high throughput identification of compounds against multiple RNA viruses. <i>Antiviral Research</i> , 2014, 107, 56-65.	4.1	18
150	Molecular epidemiology and evolution of A(H1N1)pdm09 and H3N2 virus during winter 2012-2013 in Beijing, China. <i>Infection, Genetics and Evolution</i> , 2014, 26, 228-240.	2.3	18
151	Novel host genetic variations associated with spontaneous clearance of a single-source outbreak of HCV1b infections. <i>BMJ Open Gastroenterology</i> , 2014, 1, e000010.	2.7	2
152	Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 15387.	3.3	3
153	Immunosuppressive Treatment Combined with Nucleoside Analogues Is Superior to Nucleoside Analogues Alone in the Treatment of Severe Thrombocytopenia in Patients with Cirrhosis-Associated with Hepatitis B in China: A Multicenter, Observational Study. <i>Blood</i> , 2014, 124, 2778-2778.	1.4	0
154	Association between CISH polymorphisms and spontaneous clearance of hepatitis B virus in hepatitis B extracellular antigen-positive patients during immune active phase. <i>Chinese Medical Journal</i> , 2014, 127, 1691-5.	2.3	3
155	Molecular Epidemiology of HCV in Asia. <i>Current Hepatitis Reports</i> , 2013, 12, 133-142.	0.3	1
156	A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in China. <i>Value in Health Regional Issues</i> , 2013, 2, 48-56.	1.2	10
157	APASL consensus statements and management algorithms for hepatitis C virus infection. <i>Hepatology International</i> , 2012, 6, 409-435.	4.2	152
158	Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1082-1088.	2.8	98
159	Developing a New qFIBS Model Assessing Histological Features in Pediatric Patients With Non-alcoholic Steatohepatitis. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	1